Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health.

Filters

(Clear all)

3-O-sulfated heparan sulfate translocation in altered membrane biology: A new strategy for early population screening and halting Alzheimer’s neurodegeneration

ArrestAD

ArrestAD proposes a novel and visionary thinking resulting from the demonstration of the central role of a particular heparan sulfate species at the intracellular level in neurons and in circulating cells in the molecular pathology of Alzheimer’s disease (AD). AD is a societal challenge for which there is neither prevention nor possible cure...
Funding Programme
Start Date
End Date
Total Funding
€ 3 991 096
European Countries Involved

A HOME-based Spousal caregiver-delivered music Intervention for people living with DEmentia: A Randomised Controlled Trial

HOMESIDE

Our project aims to address the need for improved informal care by training cohabitating spouse caregivers to implement music interventions that target behavioural and psychological symptoms of dementia, and the quality of life and wellbeing of people with dementia, and of family caregivers. Our international randomised controlled trial involving...
Funding Programme
Start Date
End Date
Total Funding
€ 2 400 000
European Countries Involved

ACces to Timely Formal Care

ACTIFcare

In the absence of a cure for dementia, most research is aimed at an early diagnosis as it opens the way to timely future care and treatment, and can help people take control of their lives and plan ahead. However, people with moderate to severe dementia and their carers are often not receiving services of the type, quality and timing that they need...
Funding Programme
Start Date
End Date
Total Funding
€ 2 396 428
European Countries Involved

Adaptive Implementation and Validation of the positively evaluated Meeting Centers Support Programme for people with dementia and their carers in Europe

MEETINGDEM

MEETINGDEM aims to implement and evaluate the innovative Meeting Centres Support Programme (MCSP) for community dwelling people with dementia and their family carers, in three European countries: Italy, Poland and the United Kingdom. This person-centred approach has been positively evaluated and adaptively implemented in 118 meeting centres in the...
Funding Programme
Start Date
End Date
Total Funding
€ 1 199 819
European Countries Involved

Bioactive compounds from blackcurrant processing waste for brain health

BRAINHEALTHFOOD

Alzheimer's disease (AD) is the most common age-related neurodegerative disorder, and one of the most devastating diagnoses that patients and their families can receive. Currently ~10 % of over 65 year old have AD, and the direct and indirect cost of its care is estimated to be >100 billion $ in the US alone and in the UK ~ €22M, and therefore...
Funding Programme
Start Date
End Date
Total Funding
€ 1 139 467
European Countries Involved

Biomarker based diagnosis of rapid progressive dementias – optimisation of diagnostic protocols.

DEMTEST

DEMTEST has established a large European and global collaboration between national surveillance units and dementia research centres, facilitating cooperation between neurologists, neuropathologists and neuroscientists. We work on standardisation of tests that are currently available and harmonise their use between centers worldwide. We define...
Funding Programme
Start Date
End Date
Total Funding
€ 2 200 000

Biomarkers for Alzheimer’s disease and Parkinson’s disease.

BIOMARKAPD

Neurodegenerative disorders, represented mostly by Alzheimer's disease (AD) and Parkinson's disease (PD), are characterised by progressive neuronal impairment and death. In spite of the brain's known capacity for regeneration, lost neurons generally cannot be replaced. Therefore, drugs aimed at inhibiting neurodegenerative processes are likely to...

Funding Programme
Start Date
End Date
Total Funding
€ 449 066

CO-desiGning demeNtia dIagnoSis ANd post-diagnostic CarE

COGNISANCE

People with dementia and their care partners are often dissatisfied with the process of diagnosis, communication and recommendations after diagnosis. We aim to design with people with dementia, their care partners and clinicians recommendations and campaigns for all concerned on how to improve diagnostic process and post-diagnostic care in Europe...
Funding Programme
Start Date
End Date
Total Funding
€ 1 500 000
European Countries Involved

Development of a late-onset-Alzheimer’s disease (LOAD) profile for accurate diagnosis and identification of potential therapeutic approaches

LOAD PROFILE

Late-onset Alzheimer’s disease (LOAD) is a neurodegenerative disorder that currently affects 2% of the population in industrialized countries; the risk of LOAD increases in individuals beyond the age of 70 and it is predicted that the incidence of LOAD will increase 4-fold within the next 50 years which may cause a great socioeconomic problem...

Funding Programme
Start Date
End Date
Total Funding
€ 747 300
European Countries Involved

Development of a Novel Multicellular In Vitro Model of Alzheimer’s disease-like Blood-Brain Barrier

NAB3

A striking challenge in diagnosis and therapy of neurodegenerative diseases is the design of drugs capable of crossing the blood-brain barrier (BBB), a tightly regulated barrier that prevents the passage of drugs from the blood to the brain. In vitro cellular BBB models are available, but they mimic only healthy conditions without taking into...
Funding Programme
Start Date
End Date
Total Funding
€ 812 488
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).